Abbott's FreeStyle Libre Honored with Prestigious Galien Foundation 'Golden Jubilee Award' as Part of Digital Diabetes Solutions Showcase at CIIE

On November 5, 2022, Abbott, a global leading healthcare company, showcased its full range of FreeStyle Libre digital intelligent solutions once again at the 5th China International Import Expo (CIIE). Marking the sixth anniversary of FreeStyle Libre's launch in China, Abbott held a celebratory event at the CIIE and announced a strategic partnership with the Shanghai Soong Ching Ling Foundation in the field of future medical charity. This collaboration aims to provide effective, convenient, and intelligent diabetes management support solutions for relevant populations in need.

Technology Connects Every Moment of Happiness —— Successful Hosting of the 6th Anniversary Celebration of FreeStyle Libre

On the same day, Abbott signed strategic cooperation agreements with six chain pharmacies across China: Shanghai Jiuzhou Tong Medical Device Supply Chain Company, Shanghai No. 1 Pharmacy, Shanghai Guoda Pharmacy, Shuyu Pingmin, Guangzhou Pharmaceutical, and Beijing Yuanxin Technology, as well as Huashi Pharmacy. Leveraging their respective strengths in technology and customer service, they will use the FreeStyle Libre product as a link to accelerate the creation of a comprehensive digital blood glucose monitoring and management closed-loop centered on patients, providing Chinese people with diabetes satisfactory blood sugar control experiences and service support. Additionally, Abbott awarded plaques to "Standardized Continuous Glucose Monitoring" units for the year, helping to enhance blood glucose monitoring and diabetes management levels in clinical departments of Chinese hospitals through mentoring and guidance.

"Standardized Continuous Glucose Monitoring" Unit Annual Accreditation

Guo Jing, General Manager of Abbott's Diabetes Care Business in Mainland China and Hong Kong, stated: "Abbott is committed to helping patients and healthcare professionals manage diabetes through the development of groundbreaking innovative technologies, creating a patient-centered, intelligently connected, and fully digitalized blood glucose monitoring and management closed-loop system to address the global urgent health challenge of diabetes. We also hope to continue leveraging the powerful spillover effects of the CIIE to bring FreeStyle Libre, a warm and cutting-edge technology and solution, into countless households as soon as possible, benefiting a wide range of patients and healthcare providers and supporting chronic disease management in China."

Address by Guo Jing, General Manager of Abbott Diabetes Care for Mainland China and Hong Kong
After Six Years on the Market, Established the "Gold Standard" for Continuous Glucose Monitoring in China
As the world's leading continuous glucose monitoring technology, Abbott's FreeStyle Libre flash glucose monitoring system revolutionizes traditional blood sugar testing by enabling "blood sugar measurement without finger pricks" and ushering in a new era of digital management with "scan-to-measure blood sugar" via smartphones. The system connects the smart sensor "small disc" to the FreeStyle Libre app on a smartphone, providing real-time glucose readings, glucose trend curves, historical data, and more for up to 14 days, helping users easily manage their blood sugar anytime, anywhere. A large-scale observational study by the UK Clinical Diabetes Experts Association on FreeStyle Libre users showed that those with significant improvements in TIR (time in range) not only achieved better HbA1c (glycated hemoglobin) control but also experienced fewer hypoglycemic episodes, reduced diabetes-related psychological distress, and less utilization of diabetes-related healthcare resources. Results from a health economics research report released by Chinese experts showed: for T1DM and T2DM patients on insulin therapy, compared with SMBG (self-monitoring of blood glucose), flash CGM is more cost-effective. In October this year, Abbott's FreeStyle Libre flash glucose monitoring system was awarded the "Golden Jubilee Award" by the Galien Foundation. This award recognizes outstanding scientific innovations that have contributed to improving human health since the foundation's establishment in 1970. FreeStyle Libre won the gold medal in the Best Medical Technology category. Currently, the lives of approximately 4.5 million people across more than 60 countries worldwide have benefited from it.
This year marks the sixth anniversary of FreeStyle Libre's launch in China. From the first technology in the Chinese market that allows "blood sugar testing without finger pricks," to the introduction of the FreeStyle Libre H hospital solution tailored for Chinese hospitals, and further to the digitalization with the FreeStyle LibreLink app enabling "scan with your phone to measure glucose" and the connected FreeStyle LibreLinkUp app, Abbott’s FreeStyle Libre family of products continues to expand and improve in China.
Professor Feng Bo from Oriental Hospital Affiliated to Tongji University stated: "China is the world's largest diabetes country, and all-day, scientific blood glucose monitoring is an effective means to manage diabetes well. Continuous Glucose Monitoring (CGM), as a breakthrough technology, can help patients and doctors scientifically and precisely control blood glucose, enhancing diabetes management. Abbott's FreeStyle Libre has set the gold standard for continuous glucose monitoring technology in China, and it is expected that this technology will benefit more Chinese patients and medical institutions in the future."
To provide more convenient services and benefit more patients, in addition to e-commerce platforms, Abbott currently collaborates with offline pharmacies and hospitals, supporting the establishment of hundreds of standardized continuous glucose monitoring demonstration and standard units. The FreeStyle Libre system serves over 500,000 Chinese users, supporting Chinese medical institutions in achieving scientific and standardized discipline development, enabling an increasing number of Chinese patients to meet their diabetes management needs, and helping people live healthier and better lives.
Unite Strengths to Accelerate the Development of a Digital Diabetes Management Ecosystem

As a global leader in diabetes management, Abbott has always been committed to patient-centric care, creating the FreeStyle Libre smart connected blood glucose monitoring system. Covering digital solutions from in-hospital to at-home settings, it helps Chinese diabetes patients and healthcare professionals achieve better personalized diabetes management.
For out-of-hospital scenarios, on the basis of a robust full-channel collaboration with Sinopharm Group, the Jiuzhou Tong supply chain has been introduced. Establish the "Abbott Libre Interpretation Center" to enhance the integration of online and offline services, providing consumers with more comprehensive and timely support, setting a new benchmark for chronic disease management. For in-hospital scenarios, "empowering standardized discipline construction in medical institutions," we are committed to high-level industry development, allowing more diabetes patients to enjoy a high-quality life.

Professor Feng Bo stated: "Scanning CGM currently has substantial evidence across multiple dimensions of diabetes management, demonstrating superior clinical benefits. Abbott, leveraging digital technology, is building an ecosystem for inpatient, outpatient, and home diabetes management, which will greatly enhance health benefits for patients."
During the CIIE, Abbott will continue to make efforts, exploring innovative businesses through multiple channels, both online and offline, in cooperation with Sinopharm and others. It will also carry out diverse collaborations with partners such as Yilin and the Red Cross Foundation of China, continuously expanding the digital diabetes management ecosystem while delivering cutting-edge technology with care and high-quality services. Among these initiatives, Abbott will collaborate with Boao Yilin on "pilot" projects to accelerate the introduction of new technologies into China, benefiting more patients. The company will actively explore new pathways for the digital development of diabetes patient health management, supporting the construction and upgrading of China's health industry.
For over 130 years, through cutting-edge technologies and innovative achievements in life and health, Abbott has continuously driven breakthrough innovations in prevention, monitoring, diagnosis, and treatment, shaping the future of healthcare. In the future, Abbott will continue to focus on the practical needs of diabetes management in China, constantly introducing safe, efficient, and innovative customized disease management solutions, while actively promoting industry collaboration to help more people with diabetes manage their condition scientifically and enjoy a vibrant life.